SCHEMBL25848967

SCHEMBL25848967

CNS(=O)(=O)c1ccc(C(=O)NCc2ccc(C(F)(F)F)cc2F)s1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.45
EPHX2 P34913 6/20 0.43
NR1H4 Q96RI1 3/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DDR1 Q08345 3/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
ELANE P08246 1/20 0.39
PTGER4 P35408 1/20 0.38
HDAC4 P56524 2/20 0.38
MCL1 Q07820 1/20 0.38
IL2 P60568 1/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848854 0.93 EPHX2 (0.45) TRPV1EPHX2NR1H4LMNAKMT2A
SCHEMBL24196659 0.90 MCL1 (0.42) EPHX2NR1H4LMNAKMT2ANPSR1
SCHEMBL25848961 0.89 TRPV1 (0.48) TRPV1EPHX2NR1H4LMNAKMT2A
SCHEMBL25848773 0.86 P2RX7 (0.41) EPHX2NR1H4KMT2AHDAC1HDAC6
SCHEMBL25848887 0.85 EPHX2 (0.45) EPHX2NR1H4DDR1HDAC1HDAC6
SCHEMBL25849324 0.83 PPARA (0.49) EPHX2PPARGPPARDPPARAHDAC1
SCHEMBL25848856 0.83 EPHX2 (0.43) EPHX2NR1H4DDR1HDAC1HDAC6
SCHEMBL25848848 0.82 EPHX2 (0.48) TRPV1EPHX2NR1H4DDR1PPARG
SCHEMBL25848776 0.82 EPHX2 (0.42) EPHX2DDR1PPARGPPARAHDAC1
SCHEMBL25848885 0.81 DDR1 (0.45) EPHX2DDR1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 TRPV1 330/4885EPHX2 2590/4885NR1H4 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.